Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
Doctors have used immunotherapy to treat a variety of cancers for almost five decades, and results continue to be encouraging.
People who inherit pathogenic mutations in either one of these genes have an increased risk of developing certain cancers.
Understanding the genetics of an infectious tumor in Tasmanian devils could point toward new treatment targets.
This gene is fused to many partner genes in different tumors. Now, scientists know it causes cancer — and how they might intervene.
Tumors known as gliomas generally don’t respond to the immunotherapy drugs even when the tumor cells are “hypermutated."
One finding of the project was that, on average, the genome of cancer cells contains four or five “driver” mutations.
The crowd-sourced effort has yielded unexpected findings about angiosarcoma, a disease that’s been difficult to study because it is so rare.
In support of precision medicine, a new method enables scientists to separate cancer-driving mutations from passengers.
This finding could lead to very early cancer interventions.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
New site-agnostic therapies highlight the importance of genetic testing.
Task force recommends BRCA screening for women at increased cancer risk
High-tech approach solves ‘real mystery’ in many cancers.
While most gene mutations are harmless, others are not and can spur the formation of cancer.
Dana-Farber researchers have shown that the mutated copy of the gene TP53 sabotages the normal, healthy copy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.